FindMyRecallSubscribe
Class III: unlikely to cause harmTerminated

Teva Pharmaceuticals Montelukast Sodium Oral Granules Recall

Montelukast Sodium Oral Granules USP, 4 mg, packaged in a carton containing 30 packets,…

Teva Pharmaceuticals USA Inc · Parsippany, NJ

Risk level
Class III
Reported by FDA
Apr 12, 2023
Recall ID
D-0510-2023
Check your lot numberHow we source this data

Summary

Teva Pharmaceuticals recalled Montelukast Sodium Oral Granules starting Mar 27, 2023. The FDA classified it as Class III (unlikely to cause harm) and published enforcement report D-0510-2023 on Apr 12, 2023. Reason: Failed Impurities/Degradation Specifications: failed impurities for Sulphoxide and Impurity A. Status: Terminated.

Why it was recalled

Failed Impurities/Degradation Specifications: failed impurities for Sulphoxide and Impurity A.

Product description

Montelukast Sodium Oral Granules USP, 4 mg, packaged in a carton containing 30 packets, Rx only, Distributed By: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054, Carton NDC 0093-7487-56, Packet NDC 0093-7487-19

Lot numbers, UPCs & expiration codes

Lot # 3007556A, Exp 5/2023

Where it was sold

USA Nationwide

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0510-2023
Classification
Class III
Status
Terminated
Recall initiated
Mar 27, 2023
FDA report date
Apr 12, 2023
Quantity
3,772 cartons
Recall type
Voluntary: Firm initiated
Recalling firm
Teva Pharmaceuticals USA Inc

Original FDA data

Every field from FDA enforcement report D-0510-2023, exactly as published.

Show all FDA fields
City
Parsippany
State
NJ
Status
Terminated
Country
United States
Event ID
91958
Address
400 Interpace Pkwy Bldg A
Code information
Lot # 3007556A, Exp 5/2023
Postal code
07054-1120
Report date
Apr 12, 2023
Product type
Drugs
Recall number
D-0510-2023
Classification
Class III
Recalling firm
Teva Pharmaceuticals USA Inc
Product quantity
3,772 cartons
Termination date
Aug 23, 2023
Reason for recall
Failed Impurities/Degradation Specifications: failed impurities for Sulphoxide and Impurity A.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Montelukast Sodium Oral Granules USP, 4 mg, packaged in a carton containing 30 packets, Rx only, Distributed By: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054, Carton NDC 0093-7487-56, Packet NDC 0093-7487-19
Distribution pattern
USA Nationwide
Recall initiation date
Mar 27, 2023
Initial firm notification
Letter
Center classification date
Apr 6, 2023

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0510-2023, published Apr 12, 2023. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls